sensational news:
15 August, 2007
Company Announcement
Supply and Pricing of Ropren outside Russia
The Directors of Solagran Limited are pleased to provide an update regarding the supply and
pricing of Ropren outside Russia.
Since the full results of the Ropren liver disease clinical trials were presented to 2,500
clinicians and researchers at an international gastroenterology conference in St Petersburg
in May, and particularly since Ropren received final regulatory approval from the Russian
Ministry of Health in July, Solagran and its manufacturing partner in St Petersburg have
received a steady stream of enquiries regarding the availability of Ropren for patients with
cirrhosis and other serious liver diseases living in the UK, Western Europe, Scandinavia,
North America and Asia. There have also been many enquiries from doctors in the former
Soviet Republics (CIS countries).
In response to these requests, our manufacturing partner has decided to put in place the
necessary administrative procedures to enable them to provide Ropren to patients outside
Russia consistent with the specific “compassionate use” and “personal supply” provisions
that exist within the regulatory frameworks of each country.
As part of that decision making process, it was necessary for them to consult with Solagran
to set a price for the supply of Ropren to patients outside Russia who requested supply
under the appropriate regulatory provisions. Solagran has agreed to a price in the range
3,500 to 6,000 US Dollars per three month course.
Solagran has independently confirmed that this price compares very favourably with other
therapies currently used to treat serious liver diseases.
The pricing of Ropren in Russia will be resolved with the Russian Ministry of Health in
conjunction with the granting of a manufacturing licence. This is expected to occur at the
latest in November.
Peter Stedwell
Company Secretary
On behalf of the Board of Directors
Solagran Limited
read that anyone thinking ropren would be selling for a few dollars a course :).........
- Forums
- ASX - By Stock
- SLA
- ropren pricing announcement
ropren pricing announcement
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online